537705-08-1

Basic information

• Product Name: CP-724714
• Synonyms: CP-724714;2-Methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide;(E)-Ethyl (3-(4-((3-Methyl-4-((6-Methylpyridin-3-yl)oxy)phenyl)aMino)quinazolin-6-yl)allyl)carbaMate;acetaMide, 2-Methoxy-N-[3-[4-[[3-Methyl-4-[(6-Methyl-3-pyridinyl)oxy]phenyl]aMino]-6-quinazolinyl]-2-propen-1-yl]-;(E)-Ethyl (3-(4-((3-methyl-4-((6-methylpyridin-3-yl)-oxy)phenyl)amino)quinazolin-6-yl)allyl)carba;(E)-2-Methoxy-N-(3-(4-(3-Methyl-4-(6-Methylpyridin-3-yloxy)phenylaMino)quinazolin-6-yl)allyl)acetaMide;-Ethyl (3-(4-((3-methyl-4-((6-methylpyridin-3-yl);(E)-Ethyl (3-(4-((3-methyl-4-((6-methylpyridin-3-yl)-oxy)phenyl)amino)quinazolin-6-yl)allyl)ca
• CAS NO: 537705-08-1
• Molecular Formula: C27H27N5O3
• Molecular Weight: 469.53498
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 537705-08-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 687.304 °C at 760 mmHg
• Flash Point: 369.468 °C
• Appearance: /
• Density: 1.251 g/cm³
• Solubility: ≥23.5 mg/mL in DMSO; insoluble in H2O; ≥25.4 mg/mL in EtOH
• CAS DataBase Reference: CP-724714(CAS DataBase Reference)
• NIST Chemistry Reference: CP-724714(537705-08-1)
• EPA Substance Registry System: CP-724714(537705-08-1)

Safety Data

• Hazardous Substances Data: 537705-08-1(Hazardous Substances Data)

Usage

Uses

CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM and also inhibits EGFR with IC50 of 6.4 μM.

Biological Activity

cp-724714 is an inhibitor of erbb2 and egfr kinases with ic50 values of 10±3 nmol/l and 6,400±2,100 nmol/l, respectively [1].in the in vitro cell cycle assay, cp-724714 cause a g1 block of the her2-amplified bt-474 breast cancer cells due to its inhibition of erbb2. cp-724714 at 1 ?mol/l can also reduce the level of phospho-erbb2 in these cells. in in vivo assay, cp-724714 cause a concentration-dependent reduction of tumor erbb2 receptor phosphorylation in athymic mice bearing fre-erbb2xenografts. cp-724714 treatments also resulted in a time- and dose-dependent induction of tumor cell apoptosis. in two human breast carcinoma models, bt-474 and mda-mb-453, which are her2 amplified and highly overexpress erbb2, cp-724714 is found to produce a dose-dependent inhibition of xenograft growth. in addition, cp-724,714 treatments induce reduction of downstream erbb2 rtk signaling. on the basis of these, cp-724,714 was advanced to phase i clinical trials and is potentially another option for her2-driven breast cancer [1].

references

[1] jitesh p. jani, richard s. finn, mary campbell, et al. discovery and pharmacologic characterization of cp-724714, a selective erbb2 tyrosine kinase inhibitor. cancer research. 2007 (67): 9887-9893.

Upstream product

• 38870-89-2 Methoxyacetyl chloride 
• 537705-05-8 6-iodo-N-(3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)quinazolin-4-amine 
• 537705-07-0 N-propargyl-2-methoxyacetamide 
• 3375-31-3 palladium diacetate 
• 537705-11-6 (6-chloro-quinazolin-4-yl)-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine 
• 13716-12-6 tri-tert-butyl phosphine 
• 486393-59-3 N-allyl-2-methoxyacetamide 
• 537705-10-5 (6-iodoquinazolin-4-yl)-[3-methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine hydrochloride 
• 383433-14-5 (3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}prop-2-ynyl)carbamic acid tert-butyl ester 
• 537705-06-9 3-(2-methyl-4-aminophenoxy)-6-methylpyridine 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 625-45-6 2-methoxyacetic acid 
• 16064-08-7 6-iodo-4-hydroxyquinazoline 
• 5326-47-6 2-amino-5-iodobenzoic acid 

Relevant articles and documents

Highly functionalised sulfur-based silica scavengers for the efficient removal of palladium species from active pharmaceutical ingredients

The use of multidentate sulfur-based silica scavengers 1,2, and 3 as highly effective adsorbents for the removal of precious metals, specifically palladium residues in this paper, from highly functionalised synthetic intermediates and APIs is described. The synthesis and purification of the polar and electron-rich reaction products, containing multiple functional groups, from palladium-catalysed removals of commonly used protecting groups such as benzyl, benzyloxycarbonyl, and allyloxycarbonyl and Sonogashira, Suzuki, Heck, and Buchwald-Hartwig coupling reactions is reported. The significant levels of residual palladium species, typically associated with these reaction products, are successfully and rapidly removed to below acceptable regulatory levels, of less than 5 ppm, by simple, unoptimised treatment with the designed silica scavengers at room temperature. Performance aspects, including broad solvent compatibility, excellent stability, and high metal affinity, combined with large-scale availability, ease of handling, and minimal loss of API make these silica scavengers particularly useful to process development groups.

Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer

This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide

Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide. A crystal form is useful in the synthesis of salts and complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide. A crystal form also improves stability of tabletted or capsuled E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide as a drug product.